Cargando…

Psychometric validation of the SF-36 Health Survey in light chain amyloidosis: results from community-based and clinic-based samples

BACKGROUND: Light chain (AL) amyloidosis, a rare and life-threatening protein misfolding disorder, causes organ damage and severely impacts health-related quality of life (HRQoL). No patient-reported outcome (PRO) HRQoL measure has been validated for use in an AL amyloidosis patient population, leav...

Descripción completa

Detalles Bibliográficos
Autores principales:	White, Michelle K, McCausland, Kristen L, Sanchorawala, Vaishali, Guthrie, Spencer D, Bayliss, Martha S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5724409/ https://www.ncbi.nlm.nih.gov/pubmed/29263707 http://dx.doi.org/10.2147/PROM.S146849

Ejemplares similares

Content validation of the SF-36v2® health survey with AL amyloidosis patients
por: White, Michelle K., et al.
Publicado: (2017)

The burden of amyloid light chain amyloidosis on health-related quality of life
por: Bayliss, Martha, et al.
Publicado: (2017)

Light Chain (AL) Amyloidosis: The Journey to Diagnosis
por: McCausland, Kristen L., et al.
Publicado: (2017)

A longitudinal evaluation of health‐related quality of life in patients with AL amyloidosis: associations with health outcomes over time
por: Sanchorawala, Vaishali, et al.
Publicado: (2017)

Associations between Health-Related Quality of Life and Self-Reported Emergency Room Department Visits and Inpatient Hospitalizations: Insights from a Secondary Data Analysis of Patients with Light-Chain (AL) Amyloidosis
por: McCausland, Kristen L., et al.
Publicado: (2019)

Work Outcomes Among Patients with Light Chain (AL) Amyloidosis: Findings from Three Patient Cohorts
por: Rizio, Avery A, et al.
Publicado: (2021)

Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives
por: Sarosiek, Shayna, et al.
Publicado: (2019)

Association Between Hematologic Response and Change in Health-Related Quality of Life Among Patients with Light-Chain (AL) Amyloidosis
por: Rizio, Avery A, et al.
Publicado: (2023)

Patient-reported burden of hereditary transthyretin amyloidosis on functioning and well-being
por: Lovley, Andrew, et al.
Publicado: (2021)

Sars-Cov-2 Infection and Systemic Light Chain Amyloidosis: The International Society of Amyloidosis' Survey
por: Milani, Paolo, et al.
Publicado: (2020)

Light chain amyloidosis associated with Waldenström macroglobulinemia: treatment and survival outcomes
por: Gustine, Joshua N., et al.
Publicado: (2022)

Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium
por: Lousada, Isabelle, et al.
Publicado: (2015)

Correlation Between 24-Hour Urine Protein and Random Urine Protein-Creatinine Ratio in Amyloid Light-Chain Amyloidosis
por: Mendelson, Lisa, et al.
Publicado: (2022)

Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial
por: Gertz, Morie A., et al.
Publicado: (2023)

Psychometric performance of the CAMPHOR and SF-36 in pulmonary hypertension
por: Twiss, James, et al.
Publicado: (2013)

Left Atrial Mechanics Associates With Paroxysmal Atrial Fibrillation in Light-Chain Amyloidosis Following Stem Cell Transplantation
por: Lohrmann, Graham, et al.
Publicado: (2020)

Summary of the EHA-ISA Working Group Guidelines for High-dose Chemotherapy and Stem Cell Transplantation for Systemic AL Amyloidosis
por: Sanchorawala, Vaishali
Publicado: (2022)

Psychometric Evaluation of the SF-36(®) Health Survey in Medicare Managed Care
por: Gandek, Barbara, et al.
Publicado: (2004)

Health-Related Quality of Life Instruments for Clinical Trials in AL Amyloidosis: Report from the Amyloidosis Forum HRQOL Working Group
por: Rizio, Avery A, et al.
Publicado: (2023)

Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics
por: Fraser, Cameron S., et al.
Publicado: (2022)

Light Chain Amyloidosis
por: Milani, Paolo, et al.
Publicado: (2018)

Differences in the cytogenetic underpinnings of AL amyloidosis among African Americans and Caucasian Americans
por: Staron, Andrew, et al.
Publicado: (2022)

Psychometric Evaluation of the Brunei-Malay SF-36 version 2 Health Survey
por: Alhaji, Mohammed M, et al.
Publicado: (2018)

Psychometric properties and minimal important differences of SF-36 in Idiopathic Pulmonary Fibrosis
por: Witt, Sabine, et al.
Publicado: (2019)

Improvement in Clinic Efficiency, Patient Satisfaction, and Overcoming Unique Challenges in the Era of COVID-19 with Implementation of Subcutaneous Daratumumab in Patients with Multiple Myeloma (MM) and Light Chain (AL) Amyloidosis
por: Hughes, David, et al.
Publicado: (2020)

Evaluating the Amyloidosis Speakers Bureau: the influence of amyloidosis patients’ narratives on medical students’ knowledge, attitudes, and behavioral intent
por: Adebayo, Adebanke L., et al.
Publicado: (2023)

Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities
por: Staron, Andrew, et al.
Publicado: (2020)

The Transthyretin Amyloidosis – Quality of Life (ATTR-QOL) Questionnaire: Development of a Conceptual Model and Disease-Specific Patient-Reported Outcome Measure
por: O’Connor, Meaghan, et al.
Publicado: (2023)

Complete variable domain sequences of monoclonal antibody light chains identified from untargeted RNA sequencing data
por: Nau, Allison, et al.
Publicado: (2023)

Detection of minimal residual disease by next generation sequencing in AL amyloidosis
por: Sarosiek, Shayna, et al.
Publicado: (2021)

Novel Therapies in Light Chain Amyloidosis
por: Milani, Paolo, et al.
Publicado: (2017)

DUAL expectations in light chain amyloidosis
por: Schönland, Stefan, et al.
Publicado: (2020)

Factors Influencing Disabled Stroke Survivors’ Quality of Life in Rural China: Based on the Structural Characteristics and Psychometric Properties of the SF-36 Assessment
por: Xu, Qi, et al.
Publicado: (2023)

Validation of the SF-36 in patients with endometriosis
por: Stull, Donald E., et al.
Publicado: (2013)

Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis
por: Sarosiek, Shayna, et al.
Publicado: (2020)

Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm?
por: Pickard, A Simon, et al.
Publicado: (2005)

Localized Lymph Node Light Chain Amyloidosis
por: Dhakal, Binod, et al.
Publicado: (2015)

Importance of FISH genetics in light chain amyloidosis
por: Gertz, Morie A., et al.
Publicado: (2017)

Kappa light-chain amyloidosis of gastrointestinal tract
por: Hashimoto, Rintaro, et al.
Publicado: (2019)

Multiorgan involvement by amyloid light chain amyloidosis
por: Li, Guoliang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gk6mbdetr0ipl940p9p144grbf